Developer docs
API playgroundTry for free, no card

Search company profiles

Novogene

Full company profile

uuid0000wts

Namestring
Novogene
Legal namestring
Novogene Corporation Inc.
Websiteurl
en.novogene.com
Company typeenum
Public
Founded yearint
2011
Descriptiontext

Novogene is a China-headquartered, publicly listed (Shanghai STAR market, ticker NGE) genomics sequencing services company founded in 2011 by Ruiqiang Li. It operates a global network of certified laboratories across China, the US (Sacramento and Beaverton), the UK (Cambridge), Germany (Munich), the Netherlands, Singapore, Japan, Korea, and Thailand, serving customers in 73+ countries. Its core offering is fee-for-service next-generation sequencing across the full multi-omics stack: genome, transcriptome, epigenome, metagenome, single-cell, spatial, proteomic, and metabolomic services, delivered on multiple certified sequencing platforms including Illumina, Pacific Biosciences, Oxford Nanopore Technologies, Ultima Genomics, and 10x Genomics.

The technology stack centers on the FALCON platform — described by the company as the first fully automated intelligent delivery system in the NGS industry — supplemented by the NovoMagic online RNA-seq bioinformatics tool and a Customer Service System (CSS) for project tracking. Clinical-grade services are delivered under CLIA and CAP certifications, including clinical whole exome sequencing and clinical panels for healthcare providers. Revenue is generated on a per-sample or per-project basis with published unit pricing (e.g., from $1,999 per 10x Single Cell RNA-seq sample and $3,399 per Ultima wafer for 10 billion reads), complemented by quote-based enterprise pricing for larger research programs.

The go-to-market is direct enterprise field sales targeting research institutions, universities, hospitals, pharmaceutical and biotechnology companies, and agrigenomics customers, supported by content marketing, scientific publications, and regional event participation. The company's growth strategy combines menu expansion (multiple 2025 launches across spatial, single-cell, and proteomics), geographic buildout (e.g., Korea subsidiary established June 2025), and partnership-led entry into large-scale programs such as the PRECISE-SG100K Singapore biobank. The business faces a material regulatory overhang from the June 8, 2026 U.S. Department of Defense designation of Novogene Co., Ltd. on the Section 1260H list of alleged Chinese military companies, which the company publicly disputes as erroneous and which carries downstream BIOSECURE Act procurement implications.

Short descriptiontext

Novogene is a Shanghai STAR-listed (NGE) global genomics services company offering NGS-based multi-omics sequencing (genomics, transcriptomics, epigenomics, proteomics, metabolomics) on Illumina, PacBio, ONT, and 10x platforms for research institutions, hospitals, pharma, and agrigenomics customers across 73+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSacramento, United States
HQ citystring
Sacramento
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices10 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
next-generation sequencing, multi-omics services, clinical genomics, bioinformatics analysis, genomic sequencing
Industry5 codes
PRIMARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Genomics Sequencing Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1NGS Laboratory Services
TypeUsage Based
Description

Fee-for-service laboratory testing model where customers submit biological samples for sequencing and analysis. Services include genome sequencing, transcriptome sequencing, single-cell sequencing, epigenomics, proteomics and metabolomics. Revenue is generated on a per-sample or per-project basis with pricing based on sequencing depth, sample type, and turnaround time requirements.

novogene.com
2Clinical Diagnostics Services
TypeProfessional Services
Description

Clinical-grade sequencing services including Clinical Whole Exome Sequencing (CLIA/CAP compliant) and clinical panels for healthcare providers.

novogene.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
Pricing details4 tiers
1Full Service-10x Single Cell RNA-seq
ModelUnit PricingBilling cadencePay-as-you-go
Notes

As low as $1,999 per sample for 10x Single Cell RNA sequencing services

novogene.com
2Sequencing on Ultima Genomics Platform
ModelUnit PricingBilling cadencePay-as-you-go
Notes

$3,399 per wafer for 10 billion reads

novogene.com
3Swift mRNA Sequencing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Data delivery in as little as 5 business days - premium turnaround time service

novogene.com
410x Visium HD Spatial Transcriptomics
ModelUnit PricingBilling cadencePay-as-you-go
Notes

End-to-end turnaround in as fast as 30 working days for FF/FFPE samples with up to 15% promotional discount available

novogene.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Novogene is a global provider of next-generation sequencing (NGS) services and multi-omics solutions, operating certified laboratories that perform genomic, transcriptomic, epigenomic, proteomic, and metabolomic analyses for research institutions, universities, pharmaceutical companies, and healthcare providers. The company delivers fee-for-service sequencing across multiple platforms (Illumina, Pacific Biosciences, Oxford Nanopore Technologies, Ultima Genomics) with integrated bioinformatics analysis, supported by the proprietary FALCON automated delivery platform.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Data delivery in as little as 5 business days for mRNA sequencing
+1 more record
Product overview1 text field

Novogene is a genomics services company offering a comprehensive portfolio of next-generation sequencing (NGS) services organized around core service categories: Genome Sequencing (including whole genome, exome, and de novo sequencing for human, animal, plant, and microbial samples), Transcriptome Sequencing (mRNA, non-coding RNA, small RNA, circular RNA, and isoform sequencing), Single Cell Sequencing (10x Genomics and Illumina Pip-Seq platforms with spatial transcriptomics), Epigenome Sequencing (methylation, ChIP-seq, ATAC-seq), Metagenome Sequencing (16S/18S/ITS amplicon and shotgun metagenomics), Proteomics & Metabolomics (untargeted metabolomics, lipidomics, Olink proteomics, quantitative proteomics), and Clinical Diagnostics (CLIA/CAP certified whole exome and clinical panels). These services are supported by the FALCON intelligent delivery platform for automated sample processing, NovoMagic bioinformatics analysis tools, and a Customer Service System (CSS) for project management. The company operates certified labs in the USA (California, Oregon), UK, Singapore, Japan, Korea, Germany, Netherlands, and China, utilizing sequencing platforms from Illumina, Pacific Biosciences, Oxford Nanopore Technologies, and Ultima Genomics.

Product and service12 records
1Genome Sequencing Services
CategoryGenomics Services
Description

Comprehensive genome sequencing services for human, animal, plant, and microbial samples, including Human Whole Genome Sequencing, Human/Mouse Whole Exome Sequencing, Animal and Plant De novo Sequencing, and Microbial Whole Genome Sequencing. Targeted at research institutions and pharmaceutical companies.

2Metagenome Sequencing Services
CategoryMetagenomics Services
Description

Metagenomic sequencing including 16S/18S/ITS Amplicon Metagenomic Sequencing and Shotgun Metagenomic Sequencing for microbiome analysis across human, environmental, and food science applications.

3Transcriptome Sequencing Services
CategoryTranscriptomics Services
Description

Comprehensive transcriptome analysis including mRNA Sequencing, lncRNA-seq, Small RNA Sequencing, Circular RNA Sequencing, Whole Transcriptome Sequencing, Isoform Sequencing (ISO-seq), Prokaryotic RNA Sequencing, and Metatranscriptome Sequencing.

4Single Cell Sequencing Services
CategorySingle-Cell Analysis Services
Description

Single-cell analysis services utilizing 10x Genomics and Illumina Pip-Seq platforms, including 10x Single Cell RNA-seq, Illumina Pip-Seq Single Cell 3' RNA Sequencing, and Spatial Transcriptome Sequencing for high-resolution cellular analysis.

5Epigenome Sequencing Services
CategoryEpigenomics Services
Description

Epigenetic analysis services including Whole Genome Bisulfite Sequencing (WGBS), Direct Methylation Sequencing (DM-Seq), Reduced Representation Bisulfite Sequencing (RRBS), ChIP-seq, RIP-seq, ATAC-seq, and Enzymatic Methyl Sequencing.

6Proteomics and Metabolomics Services
CategoryProteomics and Metabolomics Services
Description

Protein and metabolite profiling services including Untargeted Metabolomics, Quantitative Lipidomics, Widely-Targeted Metabolomics, Olink Reveal Proteomics, and Quantitative Proteomics powered by the Orbitrap Astral platform.

7Pre-made Library Sequencing
8Clinical Whole Exome Sequencing (CLIA/CAP)
CategoryClinical Diagnostics Services
Description

Clinical-grade whole exome sequencing service with CLIA and CAP certification for diagnostic applications, supporting rare and complex disease research and clinical testing for healthcare providers and hospitals.

9Clinical Panels
CategoryClinical Diagnostics Services
Description

Targeted clinical sequencing panels for specific disease areas and diagnostic applications, provided under CLIA/CAP clinical laboratory certifications for healthcare providers.

10FALCON Intelligent Delivery Platform
CategoryProprietary Platform
Description

The first fully automated, intelligent delivery system in the NGS industry, launched in 2020. Provides highly efficient, reliable, and flexible sample processing and data delivery for sequencing services customers.

11NovoMagic Bioinformatics Analysis Tool
CategoryBioinformatics Platform
Description

Online bioinformatics analysis platform for RNA-seq data interpretation, providing researchers with tools for data analysis and visualization.

12Customer Service System (CSS)
CategoryProject Management Platform
Description

Project management and customer service platform enabling clients to track samples, access results, and manage sequencing projects throughout the service lifecycle.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-09
Description

Thermo Fisher Scientific announced a strategic collaboration with PRECISE for the PRECISE-SG100K population-scale biobank initiative. Novogene is integrated into this collaboration as a partner for genomic sequencing services, contributing to the integration of data with global biobank efforts.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-05
Description

Novogene Europe launched a Whole Plasmid Sequencing service powered by Oxford Nanopore Technologies (ONT). The service provides complete coverage for plasmids with fast turnaround, high-quality data, and flexible throughput options for applications in gene and cell therapy, RNA therapeutics, and synthetic biology.

Strategic tierCoreTypeTechnology or Integration
Description

Novogene offers single-cell sequencing services using 10x Genomics platforms, including 10x Single Cell RNA-seq and 10x Visium HD spatial transcriptomics. The company is certified by 10x Genomics for these services.

Strategic tierCoreTypeTechnology or Integration
Description

Novogene operates Illumina-certified laboratories and offers a wide range of sequencing services on Illumina platforms including NovaSeq, NextSeq, and MiSeq systems for various applications from whole genome to targeted sequencing.

Strategic tierCoreTypeTechnology or Integration
Description

Novogene provides long-read sequencing services using Pacific Biosciences platforms for applications requiring extended read lengths, including de novo sequencing and complex structural variant analysis.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Emerging NGS instrument vendor (AVITI platform) increasingly used by independent service labs; an emerging threat to incumbent service labs like Novogene that are tied to Illumina/PacBio platforms.

TypeBroad incumbent
Description

Dominant NGS instrument and reagent vendor; also offers its own CLIA-certified clinical sequencing services (e.g., TruSight, Illumina Connected Insights), making it both a key supplier and a broad competitor across the value chain.

TypeBroad incumbent
Description

Provides genomic services through PPD and its specialty diagnostics/CDMO arms; competes with Novogene for pharma clinical trial genomics and biopharma services while also supplying it with instruments and reagents.

TypeDirect peer
Description

Global genomics services provider (formerly GENEWIZ) offering Sanger, NGS, and synthetic biology services; competes directly with Novogene in US and European research customer accounts.

TypeBroad incumbent
Description

Global molecular diagnostics and sample-prep provider with NGS-targeted bioinformatics (QIAGEN Digital Insights) and clinical genomics offerings; competes with Novogene's clinical and bioinformatics services.

TypeDirect peer
Description

US-based NGS services provider offering whole genome, exome, RNA-seq, single-cell, and microbiome sequencing to research and pharma customers; closely comparable mid-tier peer to Novogene's US sequencing business.

TypeDirect peer
Description

One of the largest global providers of genomic services (sequencing, genotyping, oligo synthesis) with deep European and US footprint; competes directly with Novogene for research institution and pharma customers.

TypeDirect peer
Description

Korean-headquartered global genomics services company offering NGS, microarray, and clinical sequencing; competes with Novogene especially across APAC and on CLIA-certified clinical sequencing projects.

TypeDirect peer
Description

Largest Chinese genomics services company, publicly listed, offering global NGS and multi-omics services directly competing with Novogene across research and clinical customers; was also added to the Pentagon 1260H list alongside Novogene.

10MGI Tech (BGI subsidiary)
TypeRegional player
Description

BGI-affiliated sequencing platform vendor (DNBSEQ) primarily serving APAC markets; competes with Novogene in Asia and represents an alternative platform ecosystem to the Illumina/PacBio/ONT stack Novogene relies on.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration6 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries10 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Novogene

Genomics Sequencing Servicesen.novogene.com

Novogene is a Shanghai STAR-listed (NGE) global genomics services company offering NGS-based multi-omics sequencing (genomics, transcriptomics, epigenomics, proteomics, metabolomics) on Illumina, PacBio, ONT, and 10x platforms for research institutions, hospitals, pharma, and agrigenomics customers across 73+ countries.

What Novogene does

Novogene is a China-headquartered, publicly listed (Shanghai STAR market, ticker NGE) genomics sequencing services company founded in 2011 by Ruiqiang Li. It operates a global network of certified laboratories across China, the US (Sacramento and Beaverton), the UK (Cambridge), Germany (Munich), the Netherlands, Singapore, Japan, Korea, and Thailand, serving customers in 73+ countries. Its core offering is fee-for-service next-generation sequencing across the full multi-omics stack: genome, transcriptome, epigenome, metagenome, single-cell, spatial, proteomic, and metabolomic services, delivered on multiple certified sequencing platforms including Illumina, Pacific Biosciences, Oxford Nanopore Technologies, Ultima Genomics, and 10x Genomics.

The technology stack centers on the FALCON platform — described by the company as the first fully automated intelligent delivery system in the NGS industry — supplemented by the NovoMagic online RNA-seq bioinformatics tool and a Customer Service System (CSS) for project tracking. Clinical-grade services are delivered under CLIA and CAP certifications, including clinical whole exome sequencing and clinical panels for healthcare providers. Revenue is generated on a per-sample or per-project basis with published unit pricing (e.g., from $1,999 per 10x Single Cell RNA-seq sample and $3,399 per Ultima wafer for 10 billion reads), complemented by quote-based enterprise pricing for larger research programs.

The go-to-market is direct enterprise field sales targeting research institutions, universities, hospitals, pharmaceutical and biotechnology companies, and agrigenomics customers, supported by content marketing, scientific publications, and regional event participation. The company's growth strategy combines menu expansion (multiple 2025 launches across spatial, single-cell, and proteomics), geographic buildout (e.g., Korea subsidiary established June 2025), and partnership-led entry into large-scale programs such as the PRECISE-SG100K Singapore biobank. The business faces a material regulatory overhang from the June 8, 2026 U.S. Department of Defense designation of Novogene Co., Ltd. on the Section 1260H list of alleged Chinese military companies, which the company publicly disputes as erroneous and which carries downstream BIOSECURE Act procurement implications.

Novogene firmographics

Firmographics
Name
Novogene
Legal name
Novogene Corporation Inc.
Website
https://en.novogene.com
Company type
Public
Founded year
2011
Operating status
Operating
Headcount range
101–250 employees
Short description
Novogene is a Shanghai STAR-listed (NGE) global genomics services company offering NGS-based multi-omics sequencing (genomics, transcriptomics, epigenomics, proteomics, metabolomics) on Illumina, PacBio, ONT, and 10x platforms for research institutions, hospitals, pharma, and agrigenomics customers across 73+ countries.
Ownership category
akta.pro rank

Novogene industry classification

Industry
Product category
Genomics Sequencing Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Next-generation sequencing
  • Multi-omics services
  • Clinical genomics
  • Bioinformatics analysis
  • Genomic sequencing

Where Novogene is headquartered

Location

Headquarters

HQ city
Sacramento
HQ country
United States
HQ region
North America

Offices10 records

Markets served

Novogene business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. NGS Laboratory Services: Fee-for-service laboratory testing model where customers submit biological samples for sequencing and analysis. Services include genome sequencing, transcriptome sequencing, single-cell sequencing, epigenomics, proteomics and metabolomics. Revenue is generated on a per-sample or per-project basis with pricing based on sequencing depth, sample type, and turnaround time requirements.
  2. Clinical Diagnostics Services: Clinical-grade sequencing services including Clinical Whole Exome Sequencing (CLIA/CAP compliant) and clinical panels for healthcare providers.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goFull Service-10x Single Cell RNA-seq
Unit PricingPay-as-you-goSequencing on Ultima Genomics Platform
Unit PricingPay-as-you-goSwift mRNA Sequencing
Unit PricingPay-as-you-go10x Visium HD Spatial Transcriptomics

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Novogene product offering

Product offering

Core offering

Novogene is a global provider of next-generation sequencing (NGS) services and multi-omics solutions, operating certified laboratories that perform genomic, transcriptomic, epigenomic, proteomic, and metabolomic analyses for research institutions, universities, pharmaceutical companies, and healthcare providers. The company delivers fee-for-service sequencing across multiple platforms (Illumina, Pacific Biosciences, Oxford Nanopore Technologies, Ultima Genomics) with integrated bioinformatics analysis, supported by the proprietary FALCON automated delivery platform.

Product overview

Novogene is a genomics services company offering a comprehensive portfolio of next-generation sequencing (NGS) services organized around core service categories: Genome Sequencing (including whole genome, exome, and de novo sequencing for human, animal, plant, and microbial samples), Transcriptome Sequencing (mRNA, non-coding RNA, small RNA, circular RNA, and isoform sequencing), Single Cell Sequencing (10x Genomics and Illumina Pip-Seq platforms with spatial transcriptomics), Epigenome Sequencing (methylation, ChIP-seq, ATAC-seq), Metagenome Sequencing (16S/18S/ITS amplicon and shotgun metagenomics), Proteomics & Metabolomics (untargeted metabolomics, lipidomics, Olink proteomics, quantitative proteomics), and Clinical Diagnostics (CLIA/CAP certified whole exome and clinical panels). These services are supported by the FALCON intelligent delivery platform for automated sample processing, NovoMagic bioinformatics analysis tools, and a Customer Service System (CSS) for project management. The company operates certified labs in the USA (California, Oregon), UK, Singapore, Japan, Korea, Germany, Netherlands, and China, utilizing sequencing platforms from Illumina, Pacific Biosciences, Oxford Nanopore Technologies, and Ultima Genomics.

Differentiator

Problem solved

Functional benefit

Products and services

  • Genome Sequencing Services Comprehensive genome sequencing services for human, animal, plant, and microbial samples, including Human Whole Genome Sequencing, Human/Mouse Whole Exome Sequencing, Animal and Plant De novo Sequencing, and Microbial Whole Genome Sequencing. Targeted at research institutions and pharmaceutical companies.
  • Metagenome Sequencing Services Metagenomic sequencing including 16S/18S/ITS Amplicon Metagenomic Sequencing and Shotgun Metagenomic Sequencing for microbiome analysis across human, environmental, and food science applications.
  • Transcriptome Sequencing Services Comprehensive transcriptome analysis including mRNA Sequencing, lncRNA-seq, Small RNA Sequencing, Circular RNA Sequencing, Whole Transcriptome Sequencing, Isoform Sequencing (ISO-seq), Prokaryotic RNA Sequencing, and Metatranscriptome Sequencing.
  • Single Cell Sequencing Services Single-cell analysis services utilizing 10x Genomics and Illumina Pip-Seq platforms, including 10x Single Cell RNA-seq, Illumina Pip-Seq Single Cell 3' RNA Sequencing, and Spatial Transcriptome Sequencing for high-resolution cellular analysis.
  • Epigenome Sequencing Services Epigenetic analysis services including Whole Genome Bisulfite Sequencing (WGBS), Direct Methylation Sequencing (DM-Seq), Reduced Representation Bisulfite Sequencing (RRBS), ChIP-seq, RIP-seq, ATAC-seq, and Enzymatic Methyl Sequencing.
  • Proteomics and Metabolomics Services Protein and metabolite profiling services including Untargeted Metabolomics, Quantitative Lipidomics, Widely-Targeted Metabolomics, Olink Reveal Proteomics, and Quantitative Proteomics powered by the Orbitrap Astral platform.
  • Pre-made Library Sequencing
  • Clinical Whole Exome Sequencing (CLIA/CAP) Clinical-grade whole exome sequencing service with CLIA and CAP certification for diagnostic applications, supporting rare and complex disease research and clinical testing for healthcare providers and hospitals.
  • Clinical Panels Targeted clinical sequencing panels for specific disease areas and diagnostic applications, provided under CLIA/CAP clinical laboratory certifications for healthcare providers.
  • FALCON Intelligent Delivery Platform The first fully automated, intelligent delivery system in the NGS industry, launched in 2020. Provides highly efficient, reliable, and flexible sample processing and data delivery for sequencing services customers.
  • NovoMagic Bioinformatics Analysis Tool Online bioinformatics analysis platform for RNA-seq data interpretation, providing researchers with tools for data analysis and visualization.
  • Customer Service System (CSS) Project management and customer service platform enabling clients to track samples, access results, and manage sequencing projects throughout the service lifecycle.

Quantifiable outcome

  • Data delivery in as little as 5 business days for mRNA sequencing
  • +1 more outcomes

Companies that use Novogene

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Novogene technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration6 records

Feature5 records

Novogene partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Precision Health Research, Singapore (PRECISE)coreStrategic or Co-development Partner · 9 April 2026Thermo Fisher Scientific announced a strategic collaboration with PRECISE for the PRECISE-SG100K population-scale biobank initiative. Novogene is integrated into this collaboration as a partner for genomic sequencing services, contributing to the integration of data with global biobank efforts.
  • Oxford Nanopore Technologies (ONT)coreTechnology or Integration · 5 November 2025Novogene Europe launched a Whole Plasmid Sequencing service powered by Oxford Nanopore Technologies (ONT). The service provides complete coverage for plasmids with fast turnaround, high-quality data, and flexible throughput options for applications in gene and cell therapy, RNA therapeutics, and synthetic biology.
  • 10x GenomicscoreTechnology or IntegrationNovogene offers single-cell sequencing services using 10x Genomics platforms, including 10x Single Cell RNA-seq and 10x Visium HD spatial transcriptomics. The company is certified by 10x Genomics for these services.
  • IlluminacoreTechnology or IntegrationNovogene operates Illumina-certified laboratories and offers a wide range of sequencing services on Illumina platforms including NovaSeq, NextSeq, and MiSeq systems for various applications from whole genome to targeted sequencing.
  • Pacific Biosciences (PacBio)coreTechnology or IntegrationNovogene provides long-read sequencing services using Pacific Biosciences platforms for applications requiring extended read lengths, including de novo sequencing and complex structural variant analysis.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Novogene competitors and assessment

Company assessment

Emerging players

  • Element Biosciences: Emerging NGS instrument vendor (AVITI platform) increasingly used by independent service labs; an emerging threat to incumbent service labs like Novogene that are tied to Illumina/PacBio platforms.

Broad incumbents

  • Illumina: Dominant NGS instrument and reagent vendor; also offers its own CLIA-certified clinical sequencing services (e.g., TruSight, Illumina Connected Insights), making it both a key supplier and a broad competitor across the value chain.
  • Thermo Fisher Scientific: Provides genomic services through PPD and its specialty diagnostics/CDMO arms; competes with Novogene for pharma clinical trial genomics and biopharma services while also supplying it with instruments and reagents.
  • QIAGEN: Global molecular diagnostics and sample-prep provider with NGS-targeted bioinformatics (QIAGEN Digital Insights) and clinical genomics offerings; competes with Novogene's clinical and bioinformatics services.

Direct peers

  • Azenta Life Sciences (GENEWIZ): Global genomics services provider (formerly GENEWIZ) offering Sanger, NGS, and synthetic biology services; competes directly with Novogene in US and European research customer accounts.
  • CD Genomics: US-based NGS services provider offering whole genome, exome, RNA-seq, single-cell, and microbiome sequencing to research and pharma customers; closely comparable mid-tier peer to Novogene's US sequencing business.
  • Eurofins Genomics: One of the largest global providers of genomic services (sequencing, genotyping, oligo synthesis) with deep European and US footprint; competes directly with Novogene for research institution and pharma customers.
  • Macrogen: Korean-headquartered global genomics services company offering NGS, microarray, and clinical sequencing; competes with Novogene especially across APAC and on CLIA-certified clinical sequencing projects.
  • BGI Genomics: Largest Chinese genomics services company, publicly listed, offering global NGS and multi-omics services directly competing with Novogene across research and clinical customers; was also added to the Pentagon 1260H list alongside Novogene.

Regional players

  • MGI Tech (BGI subsidiary): BGI-affiliated sequencing platform vendor (DNBSEQ) primarily serving APAC markets; competes with Novogene in Asia and represents an alternative platform ecosystem to the Illumina/PacBio/ONT stack Novogene relies on.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Novogene social profiles

Digital presence

Novogene compliance and trust

Trust signal

Compliance2 records

Novogene financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Novogene leadership team

Management profile

Number of profiles

Profiles1 record

Novogene subsidiaries and ownership

Company hierarchy

Subsidiaries10 records

Novogene funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Novogene M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novogene

What does Novogene do?

Novogene is a global provider of next-generation sequencing (NGS) services and multi-omics solutions, operating certified laboratories that perform genomic, transcriptomic, epigenomic, proteomic, and metabolomic analyses for research institutions, universities, pharmaceutical companies, and healthcare providers. The company delivers fee-for-service sequencing across multiple platforms (Illumina, Pacific Biosciences, Oxford Nanopore Technologies, Ultima Genomics) with integrated bioinformatics analysis, supported by the proprietary FALCON automated delivery platform.

Is Novogene a public or private company?

Novogene is a public company. It is classified as public and is currently operating.

When was Novogene founded?

Novogene was founded in 2011. It employs 101 to 250 people.

Where is Novogene based?

Novogene is headquartered in Sacramento, United States, in the North America region.

How does Novogene make money?

Two revenue lines are on record. NGS Laboratory Services are the primary driver. The others are clinical Diagnostics Services.

Who are Novogene's main competitors?

Element Biosciences is listed as an emerging player. Broad incumbents are Illumina, Thermo Fisher Scientific and QIAGEN. Direct peers are Azenta Life Sciences (GENEWIZ), CD Genomics, Eurofins Genomics, Macrogen and BGI Genomics. MGI Tech (BGI subsidiary) is listed as a regional player.

Does Novogene have an API?

No public API is recorded for Novogene.

What industry is Novogene in?

Novogene's product category is Genomics Sequencing Services. Its primary akta.pro industry code is HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services, with a secondary code of HLAGANAE, Transcriptomics & Gene Expression Profiling Services. Its NAICS code is 5417 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Defense PostNovogene Takes Pentagon to Court Over Alleged Ties to China’s MilitaryNovogene sued the US Defense Department over its designation as a company supporting China's military, arguing the decision is unlawful and has harmed its business and reputation. The lawsuit challenges its inclusion on the Pentagon's list, which bars direct contracts and will restrict third-party purchases in 2027. Other Chinese firms, including Alibaba and DJI, are also contesting their listings.The Times of IndiaChinese genetic sequencing firm Novogene sues Pentagon over military blacklistNovogene sued the US Department of Defense in Washington, challenging its inclusion on the Pentagon's list of Chinese military companies. The company argues the designation is unlawful and has caused reputational and economic harm, while the Pentagon has not responded. The designation bars direct contracts and will extend to third-party purchases from 2027.Channel NewsAsiaChinese genetic firm Novogene sues US over military designationNovogene sued the Pentagon in US District Court over its inclusion on a list of Chinese military companies. The company said its US unit employs about 180 people and the designation is unlawful, causing harm. The designation restricts Pentagon purchases through third parties starting in 2027.MarketScreenerChinese genetic firm Novogene sues US over military designationNovogene sued the Pentagon in U.S. District Court over its inclusion on a list of Chinese military companies. The Defense Department added Novogene, Alibaba, Baidu, BYD, and NIO to the list in June, which bars direct contracting. Other Chinese firms have also sued over the designations.MoomooNovogene (688315.SH) announced its performance results for the first three quarters, with net profit attributable to shareholders of the listed company reaching RMB 96.0979 million, a year-on-year decline of 14.87%.Novogene reported its third-quarter 2026 results, with operating revenue of RMB 1.67 billion, up 5.67% year over year. Net profit attributable to shareholders fell 14.87% to RMB 96.0979 million, and basic earnings per share were RMB 0.24.News-MedicalUnlocking drug discovery: The power of omics technologiesDr. Shi-Qi An, Director of Marketing and Science Communications at Novogene Europe, discusses how integrating genomics, transcriptomics, proteomics, and metabolomics can uncover complex biological mechanisms and support drug discovery. She emphasizes that single-cell and spatial omics are valuable for heterogeneous populations, but researchers must match technology to their specific questions. She also notes that bioinformatics should be part of experimental design to ensure meaningful interpretation.PR NewswireGlobal genomics and multi-omics leader Novogene to establish its first Australian laboratory at Cabrini Health, accelerating access to precision cancer careNovogene will establish its first Australian laboratory at Cabrini Health in Melbourne, expected to open in 2027. The joint lab will integrate genomic testing into clinical care, supported by a $10 million PMF Foundation grant and a $5 million Australian Government grant. It aims to speed biopsy-to-result turnaround and support clinical trials.PR Newswire APACGlobal genomics and multi-omics leader Novogene to establish its first Australian laboratory at Cabrini Health, accelerating access to precision cancer careNovogene announced on August 28, 2026 that it will open its first Australian laboratory at Cabrini Health in Malvern, co-located within the private hospital's clinical and cancer research precinct. Expected to open in 2027, the facility will deliver genomic results within days, supported by a $10 million PMF Foundation grant and a $5 million Australian Government grant. Novogene plans to hire and train Australian staff and strengthen local collaborations.ThemalaysianreserveGlobal genomics and multi-omics leader Novogene to establish its first Australian laboratory at Cabrini Health, accelerating access to precision cancer careNovogene will open its first Australian laboratory at Cabrini Health in Melbourne, expected in 2027. The lab will integrate genomic testing into Cabrini's cancer services, which deliver about 30,000 treatments and 4,000 diagnoses annually. The initiative is supported by a $10 million grant from the PMF Foundation and a $5 million Australian Government grant.News-MedicalNovogene Europe expands single-cell sequencing capability at Cambridge Omics CentreNovogene Europe announced the expansion of its single-cell RNA sequencing capability at its Cambridge Omics Centre, bringing 10x Genomics Chromium-based workflows closer to UK academic, biotech, and biopharma researchers. The service includes sample processing, quality control, library preparation, sequencing, and bioinformatics analysis across oncology, immunology, neuroscience, and drug discovery applications. The expansion marks the next phase of capability development at the Cambridge site and coincides with Novogene's 15th anniversary year.